2007至2016年间，标准普尔500指数中的19家制药公司（截至2017年1月）花了2,970亿美元用于回购股份和提振股价，从而提升高管股票期权的价值。
Between 2007 and 2016, the 19 pharmaceutical companies in the S&P 500 as of January 2017 spent $297 billion repurchasing their own shares to boost their stock price, and thus the value of their executives’ stock options.